

FOI 3656

25th March 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Response:

Name of medicine	Number patients treated
1.1 Acalabrutinib (Calquence)	31
1.2 Ibrutinib (Imbruvica)	10
1.3 Pirtobrutinib (Jaypirca)	0
1.4 Venetoclax (Venclyxto)	9
1.5 Zanubrutinib (Brukinsa)	7
1.6 Rituximab	67
1.7 Obinutuzumab (Gazyvaro)	18

Q2. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Name of medicine	Number patients treated
2.1 Acalabrutinib (Calquence)	
2.2 Ibrutinib (Imbruvica)	
2.3 Pirtobrutinib (Jaypirca)	
2.4 Venetoclax (Venclyxto)	

2.5 Zanubrutinib (Brukinsa)	
2.6 Obinutuzumab (Gazyvaro)	
2.7 Rituximab	

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q3. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
3.1 Ibrutinib + Venetoclax	
3.2 Obinutuzumab + Venetoclax	
3.3 Ibrutinib monotherapy / maintenance	
3.4 Venetoclax monotherapy	
3.5 Venetoclax + Rituximab	
3.6 Rituximab monotherapy	
3.7 Rituximab + Fludarabine + Cyclophosphamide	
3.8 Rituximab + R-CHOP	
3.9 Rituximab + Bendamustine	
3.10 Rituximab + Chlorambucil	
3.11 Obinutuzumab + Chlorambucil	

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q4. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
4.1 Acalabrutinib	
4.2 Ibrutinib	
4.3 Zanubrutinib	
4.4 Ibrutinib + R-CHOP / R-DHAP	
4.5 Pirtobrutinib	

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if

information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q5. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Name of medicine	Number patients treated
5.1 Azacitidine	
5.2 Cytarabine	
5.3 Venetoclax (Venclyxto)	

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q6. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Name of combination	Number patients treated
6.1 Venetoclax + Azacitidine (with or without posaconazole)	
6.2 Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C)	

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of all admissions and A&E attendances just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q7. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Response:

Name of medicine	Number patients treated
8.1 Fedratinib (Inrebic)	2
8.2 Mometinib (Omjara)	4
8.3 Ruxolitinib (Jakavi)	19
8.4 Hydroxycarbamide	158

Q8. How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Name of medicine	Number patients treated
9.1 Ruxolitinib (Jakavi)	
9.2 Hydroxycarbamide	

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Email: Foi.Team@Southerntrust.hscni.net